REGN17372
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 07, 2026
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1/2 | N=150 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
First-in-human • New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1